Epidemiological studies have established that left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular and cerebrovascular morbidity and mortality. In turn, hypertension is a well-established risk factor for LVH. Ambulatory blood pressure monitoring has shown that 24-h mean ambulatory blood pressure is a particularly powerful predictor of LVH, being superior to casual clinic blood pressure measurements. The magnitude of the rise in blood pressure in the early morning correlates with the extent of LVH. Prospective studies have shown the advantageous effects of antihypertensive therapy on LVH in terms of regression of left ventricular mass (LVM) and subsequent reduction in overt cardiovascular disease. Meta-analysis has identified differences in the ability of different classes of anti-hypertensive agents to bring about regression of LVH, with agents that target the reninangiotensin system (RAS) appearing superior to other agents, such as b-blockers and diuretics. The distinct pharmacological features of telmisartan suggest that it may be a suitable agent for managing hypertensive patients because it provides sustained control of blood pressure and appears to be very effective in reversing cardiac remodelling.
Introduction
Since its inception in 1948, the Framingham Heart Study has made many important contributions to our understanding of heart disease and the identification of risk factors. Using baseline findings and serial changes in electrocardiograms (ECGs) of patients with left ventricular hypertrophy (LVH), epidemiological data established that LVH is a risk factor for cardiovascular morbidity and mortality. 1 The Framingham Heart Study demonstrated that LVH is an independent predictor of coronary disease, congestive heart failure and peripheral arterial disease. With the introduction of echocardiography for the evaluation of LVH, the Framingham Heart Study was able to assess accurately its prevalence and has established that, after adjusting for other cardiovascular disease risk factors, the presence of LVH is associated with a doubling in mortality. 2 Left ventricular hypertrophy identified by ECG is also a powerful predictor of cerebrovascular events. 1 Furthermore, in a follow-up of over 2000 apparently healthy subjects with hypertension, LVH diagnosed by echocardiography has been shown to confer an excess risk for stroke and transient ischaemic attack that is again independent of blood pressure and other individual risk factors. 3 More recent evidence for the strong, continuous, independent relationship between LVH and subsequent cardiovascular morbidity comes from the MAssa Ventricolare sinistra nell'Ipertensione (MAVI) study. 4 After adjustment for age, cigarette smoking, diabetes and serum creatinine, LVH identified by echocardiography was found to be associated with increased cardiovascular risk and, for each 39 g/m 2 increase in left ventricular mass (LVM), there was an independent 40% rise in the likelihood of a patient experiencing a major cardiovascular event.
Importance of hypertension in LVH
The prevalence of structural cardiac abnormalities is high in hypertensive patients. 5 When compared with normotensive subjects, LVH (determined by LVM, left ventricular wall thickness index and wall thickness: radius ratio) has been identified in as many as 40% of patients with mild hypertension, and even more frequently in those with established more severe hypertension. In addition, abnormalities in the transmitral flow velocity are more prevalent in patients whose blood pressure is only mildly elevated, particularly in patients with established hypertension, compared with their normotensive counterparts. 5 Information on the powerful relationship between LVM and risk of cardiovascular disease in subjects with uncomplicated essential hypertension, established using 24-h mean ambulatory blood pressure monitoring (ABPM), is provided by a study conducted in nearly 2000 white subjects followed up over a mean of 4 years. 6 Dividing patients into quintiles according to their LVM at the start of the study, a progressive increase in adjusted relative risk of a cardiovascular event was identified over the range of LVM values. In the highest quintile, there was a 3.5-fold greater incidence compared with the lowest quintile. Furthermore, there was an increase in the relative risk in patients with blood pressure regarded as being below the so-called 'upper normal' limits.
Data obtained from 24-h ABPM provide a more accurate prediction of LVH than office blood pressure measurements. 7 It has been shown that hypertensive patients whose ambulatory blood pressure readings are notably higher than one would predict from clinical blood pressure readings are at highest risk of LVH, which suggests that abnormalities in the circadian rhythm are important prognostic indicators. For example, for any given level of 24-h mean blood pressure, a flattened diurnal blood pressure profile is associated with a greater LVM in hypertensive women. 8 Daytime hypertension, whether or not associated with a blunted nocturnal fall in blood pressure, may be a determinant of left ventricular wall thickening in men. 8 Particularly important is the extent of the early morning rise in blood pressure and its impact on LVH. Hypertensive patients with a ≥ 10 mmHg increase in blood pressure on arising displayed an increase in end-diastolic wall thickness 9 and LVM. 9,10
Use of anti-hypertensives in the control of LVH
In the light of the evidence that high blood pressure is a powerful risk factor for LVH, it is logical to deduce that aggressive control of hypertension that includes the early morning blood pressure surge should bring about regression of LVH and improve patient prognosis. Prospective studies have shown that anti-hypertensive treatment brings about LVH regression 11 and that regression of LVM is a favourable prognostic marker, predicting a reduced risk of subsequent cardiovascular morbid events. 12 Metaanalysis confirms that LVH regression during anti-hypertensive treatment is associated with a marked reduction in the risk of subsequent cardiovascular disease. 13 There is, however, the issue of whether all anti-hypertensive agents are equally effective or whether some classes are better than others because of differences in mechanisms of action, pharmacodynamics and pharmacokinetics. The 1999 World Health Organization -International Society of Hypertension Guidelines for the Management of Hypertension, in acknowledging the potential long-term impact of sustained antihypertensive activity, recommend use of longacting anti-hypertensive agents to control blood pressure. 14 Recent meta-analysis of randomized, double-blind clinical trials evaluating the effects of diuretics, β-blockers, calcium channel blockers, angiotensinconverting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on echocardiographically assessed LVM regression in hypertensive patients has identified the potential benefit of targeting the reninangiotensin system (RAS). 15 The findings suggest that use of an ARB may be especially advantageous in reducing LVM ( Fig. 1 ). After adjustment for the duration of treatment and change in diastolic blood pressure (DBP), ARBs brought about a 13% regression of the LVM index (LVMI) as opposed to only 8% with diuretics and 6% with β-blockers.
Telmisartan is an ARB that has been shown in clinical trials using ABPM to provide 24-h blood pressure control 16 and to be effective even if a dose is missed. 17 The sustained antihypertensive activity of telmisartan may be attributed to its terminal elimination halflife of about 24 h. 18 Another distinguishing feature of telmisartan is its lipophilicity, which may enhance tissue penetration. 19
Pre-clinical evaluation of telmisartan

IN VITRO FINDINGS
In LVH, collagen accumulates in the myocardium of the left ventricle. 20 An in vitro model has been developed to simulate this myocardial fibrosis. The addition of angiotensin II to cultured adult rat cardiac fibroblasts dose dependently stimulated the production and secretion of collagen. 21 Pretreatment of the fibroblasts with telmisartan completely blocked the angiotensin II-induced collagen synthesis and secretion. The study further showed that the effect of P Verdecchia Telmisartan in cardiac remodelling
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angiotensin II is specific to the stimulation of the angiotensin II type 1 (AT 1 ) receptor, which is blocked by telmisartan, as when an AT 2 -specific receptor antagonist, P-186, was added to the cultured fibroblasts there was no effect on collagen production and secretion.
ANIMAL MODELS OF HYPERTENSION
In rats rendered hypertensive by aortic banding, telmisartan reduced blood pressure and cardiac mass. 22 Other studies suggest that the effect of telmisartan may not be exclusively due to a reduction in blood pressure, and hence work load. In strokeprone, spontaneously hypertensive rats, for example, administration of telmisartan, captopril or losartan resulted in similar reductions in blood pressure. 23 However, the effects of the different anti-hypertensive agents on the left ventricle varied, with only telmisartan reducing left ventricular and septal weight. Furthermore, in transgenic TGR(mREN2)27 rats, telmisartan at doses of 0.1 -10 mg/kg per day brought about statistically significant reductions in cardiac hypertrophy, 24 but the lowest dose evaluated did not have any effect on blood pressure.
PREVENTION OF CARDIAC HYPERTROPHY
Two animal models have demonstrated the advantageous effects of telmisartan in preventing cardiac hypertrophy. In mice treated with isoproterenol to induce increases in cardiac mass, the hypertrophy was attenuated by telmisartan treatment. 25 In rats with aortocaval shunt as an experimental model of chronic heart failure, telmisartan prevented heart mass increase. The effect was blunted by an AT 2 antagonist, suggesting an additional non-haemodynamic effect of telmisartan in targeting the RAS by allowing stimulation of the AT 2 receptor. 22
ANIMAL MODEL OF HYPERTENSION AND DIABETES
The combination of diabetes and hypertension is frequently associated with LVH. Spontaneously hypertensive rats were rendered diabetic by the administration of streptozotocin. Long-term treatment of these animals with either telmisartan or lisinopril resulted in comparable reductions in blood pressure and left ventricular and septum weights. 26 
Clinical evaluation of telmisartan EFFECT ON LVH REGRESSION IN MILD-TO-MODERATE HYPERTENSION
In an open-label, prospective study of 85 hypertensive patients with mild-to-moderate LVH, telmisartan reduced systolic blood pressure (SBP) and DBP. 27 These reductions in blood pressure were accompanied by a time-dependent, significant reduction in LVMI from 119 ± 7 to 109 ± 3 g/m 2 (P < 0.001) (Fig. 2) , determined using twodimensional echocardiography, over the 12-month study period. Another noncomparative study of 2 years' duration showed, using two-dimensional echocardiography, that telmisartan reduced LVM in 76 patients with newly diagnosed hypertension. 28 A third two-dimensional echocardiographic study that had a double-blind design has been performed in 30 hypertensive patients. 29 In that study, 70% of patients were newly diagnosed as hypertensive, and LVH was present in only 30% of patients. Despite the relatively low LVMIs at baseline, LVM was reduced after 6 months' treatment with either telmisartan or losartan. The study, however, was not sufficiently powered to identify any differences between the two ARB treatments.
Although widely used to diagnose LVH and generally regarded as being reliable, M-mode and two-dimensional echocardiography require geometrical assumptions and can lead to errors in image plane positioning that decrease the accuracy of LVM and left ventricular volume measurements. 30 The problem is greatest in subjects with abnormally shaped left ventricles, as often occurs in hypertensive patients. 31 The more recently developed three-dimensional echocardiography may overcome the need for any geometric assumptions.
Dynamic, freehand, three-dimensional echocardiography detected a significantly greater decrease in LVMI after 12 months in the 40 patients treated with telmisartan compared with the 25 patients treated with hydrochlorothiazide (HCTZ) (Fig. 3 ). 32 The 
P Verdecchia Telmisartan in cardiac remodelling
regression of LVH may be attributed to the reduction in blood pressure as telmisartan also produced a statistically significantly greater reduction in 24-h mean ambulatory SBP and DBP compared with HCTZ. Another study by the same investigators suggests that the beneficial effects of telmisartan may not be exclusively due to its anti-hypertensive activity. In addition to three-dimensional echocardiography, magnetic resonance imaging (MRI) of the heart was performed. MRI is now regarded as the gold standard for clinical trials because it provides highquality images and is capable of detecting 1 mm changes in left ventricular wall thickness. In the 82 evaluated patients with hypertension and LVH, it was demonstrated that telmisartan was superior to carvedilol in reducing LVM, despite both drugs producing similar reductions in blood pressure. 33
EFFECT ON LEFT VENTRICULAR FUNCTION
Systolic function tends to remain normal in the presence of LVH, but diastolic filling patterns are frequently altered. Severe pressure overload eventually leads to systolic function becoming impaired and left ventricular failure. Telmisartan has been shown, using two-dimensional echocardiography, to improve left ventricular function, even before regression of LVM is detectable. After 1 month of telmisartan treatment, left ventricular stroke work was reduced, and brachial artery and systemic vascular stroke volume were increased. 34 It has also been shown that, given in combination with diuretics and carvedilol, telmisartan improved left ventricular end-diastolic diameter and ejection fraction, measured using echocardiography, in patients with hypertensive cardiopathy and ischaemic heart disease. 35 Favourable effects were observed after 3 months' treatment, and further improvements were detected over the 12-month duration of the study. Another study showed improvement in left ventricular function that was apparent soon after initiation of treatment. 36 A reduction in the peak rate of ventricular pressure development was detected after administration of telmisartan for 4 weeks. Further 18A P Verdecchia Telmisartan in cardiac remodelling benefit of telmisartan was demonstrated in this study, as an improvement in vascular stiffness was also detected.
In a comparison of telmisartan and valsartan, both drugs reduced blood pressure after 4 weeks' treatment. In addition, telmisartan improved afterload and contractility index, by reducing systemic vascular resistance and increasing vascular compliance, whereas valsartan had no effect on afterload and only increased vascular compliance. 37 Haemodynamic differences between telmisartan and amiloride have also been observed. 38 Both agents reduced SBP and DBP, but telmisartan improved afterload and contractility index, reduced systemic vascular resistance and increased systemic vascular compliance. In contrast, amiloridetreated patients only displayed improvements in contractility index and increased vascular compliance.
EFFECT ON LEFT ATRIAL VOLUME AND FUNCTION
Chronic hypertension can result in an increase in left atrial volumes, a decrease in left atrial passive emptying function and an increase in systolic pump function. 39 Increased left atrial pump function represents a compensatory mechanism in hypertensive patients with LVH. The LVH regression observed by Mattioli et al. 27 in hypertensive patients treated with telmisartan for 1 year also brought about a reduction in left atrial size and volume, and improvement in atrial performance. 40 In addition, there was an improvement in the early to atrial filling ratio.
Conclusions
Pre-clinical studies provide evidence that telmisartan has beneficial effects on cardiac hypertrophy and improves cardiac function. The data also suggest that these effects may not be exclusively due to blood pressure control, and that telmisartan may confer additional benefits compared with other agents that target the RAS. Findings from relatively small-scale clinical studies demonstrate that telmisartan is able to bring about regression of LVH in patients with mild-tomoderate hypertension and, thus, may have cardioprotective properties. Furthermore, reduction of LVM appears to be induced in hypertensive patients not yet displaying overt LVH. The regression may, in part, be due to the concurrent reduction in blood pressure recorded in these studies, but also may arise from non-haemodynamic mechanisms as a result of the targeting of the RAS. There are also some data that suggest a distinction between different ARBs that may be linked to the variations in the drugs' physicochemical properties 19 and the effect on tissue penetration, as well as the longer duration of anti-hypertensive activity with telmisartan. 16, 17 Results from telmisartan clinical studies are consistent with the observation that angiotensin II stimulates LVH in hypertension, independently of the level of blood pressure. 41 Admittedly, to date, most studies evaluating the effect of telmisartan on LVH have been conducted in small groups of patients with only mild-to-moderate hypertension and no confounding factors, such as diabetes. The ultimate proof of the clinical value of telmisartan will be provided by large-scale outcome studies in high-risk patients, testing also the hypothesis that regression of LVH induced by this drug is associated with improved cardiovascular outcome. For example, the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) trials will consider the effects of telmisartan given alone or in combination with ramipril on
